2020
Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer
Shuch B, Li S, Risch H, Bindra RS, McGillivray PD, Gerstein M. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. Cancer 2020, 126: 3657-3666. PMID: 32413184, PMCID: PMC10316675, DOI: 10.1002/cncr.32914.Peer-Reviewed Original ResearchConceptsFumarate hydrataseExome Aggregation ConsortiumAllele frequenciesFH geneGenome ProjectDifferent world populationsFH alterationsHereditary leiomyomatosisKidney cancer riskCancer penetranceMissense alterationsGenesOverall allele frequencyRare variantsLow penetranceRenal cancerExACKidney cancerCancer riskPenetranceGermline mutationsLethal formWorld populationCancer syndromesAlterations
2018
The Higher the Grade, the Bigger the Field
Beckta JM, Bindra RS. The Higher the Grade, the Bigger the Field. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: 488-489. PMID: 30238899, DOI: 10.1016/j.ijrobp.2018.08.019.Peer-Reviewed Original ResearchResidual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging
Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers A, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon K, Wen PY, Bindra RS, Woo J, Arnaout O, Gerstner ER, Zhang PJ, Rosen BR, Yang L, Huang RY, Kalpathy-Cramer J. Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging. Clinical Cancer Research 2018, 24: clincanres.2236.2017. PMID: 29167275, PMCID: PMC6051535, DOI: 10.1158/1078-0432.ccr-17-2236.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrainBrain NeoplasmsDatasets as TopicFemaleGliomaHumansImage Processing, Computer-AssistedIsocitrate DehydrogenaseMagnetic Resonance ImagingMaleMiddle AgedMutationNeoplasm GradingNeural Networks, ComputerPredictive Value of TestsPreoperative PeriodRetrospective StudiesYoung AdultConceptsResidual convolutional neural networkConvolutional neural networkNeural networkDeep learning techniquesTesting setNeural network modelMulti-institutional data setCancer Imaging ArchiveLearning techniquesTesting accuracyNetwork modelTraining setPrediction accuracyPreoperative radiographic dataClin Cancer ResData setsConventional MR imagingHospital of UniversityIsocitrate dehydrogenase (IDH) mutationPreoperative imagingLonger survivalWomen's HospitalGrade IINetworkTreatment decisionsYale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/s1470-2045(17)30916-6.Peer-Reviewed Case Reports and Technical Notes
2017
Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery
Chowdhary M, Okwan-Duodu D, Switchenko JM, Press RH, Jhaveri J, Buchwald ZS, Zhong J, Chapman BV, Bindra RS, Contessa JN, Park HS, Yu JB, Decker RH, Olson JJ, Oyesiku NM, Abrams RA, Shu HG, Curran WJ, Crocker IR, Patel KR. Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. Journal Of Neuro-Oncology 2017, 136: 289-298. PMID: 29124649, PMCID: PMC5784434, DOI: 10.1007/s11060-017-2652-0.Peer-Reviewed Original ResearchConceptsSymptomatic radiation necrosisOverall survivalStereotactic radiosurgeryIntracranial efficacyRadiation necrosisKaplan-Meier methodLate radiation toxicitySignificant predictive factorsArteriovenous malformation patientsCumulative incidence modelsIntracranial outcomesBaseline characteristicsBlockade therapyBrain metastasesProspective trialABT groupConsecutive patientsMedian ageMeier methodPreclinical evidencePredictive factorsAVM cohortsRadiation toxicityPrognostic analysisMultivariate analysisPatterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas
Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB. Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy And Oncology 2017, 125: 258-265. PMID: 29054377, DOI: 10.1016/j.radonc.2017.09.027.Peer-Reviewed Original ResearchConceptsUse of CCRTConcurrent chemoradiotherapyPatterns of careAnaplastic gliomasOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingMultivariable logistic regression analysisConcurrent CRTNational Cancer DatabaseKaplan-Meier analysisLog-rank testLogistic regression analysisGrade III gliomasAdjusted hazardAdult patientsImproved survivalCancer DatabaseDesign cohortRadiotherapyPropensity scorePatientsGliomasChemoradiotherapyRegression modelingBi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis‐Filho J, Powell SN. Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. The Journal Of Pathology 2017, 242: 165-177. PMID: 28299801, PMCID: PMC5516531, DOI: 10.1002/path.4890.Peer-Reviewed Original ResearchConceptsBreast cancerGermline BRCA1/BRCA2 mutationsBRCA1/BRCA2 mutationsPrecision medicine-based approachPrimary breast cancerTumour-specific DNA repair defectsSporadic breast cancerGermline genetic alterationsBi-allelic lossWhole-exome sequencingSpecific mutational signaturesComprehensive genetic assessmentBRCA2 mutationsLarge-scale state transitionsBi-allelic alterationsCancerGenetic alterationsDNA repair defectsMutational signaturesTherapyAlterationsRepair defectsGene expressionGenetic assessmentHR genes
2016
Adjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factors